Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar B. Jeon JY, et al. Among authors: mims as. Invest New Drugs. 2020 Apr;38(2):340-349. doi: 10.1007/s10637-019-00786-4. Epub 2019 May 17. Invest New Drugs. 2020. PMID: 31102119 Free PMC article. Clinical Trial.
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G. Mims A, et al. Leukemia. 2013 Apr;27(4):871-8. doi: 10.1038/leu.2012.342. Epub 2012 Nov 26. Leukemia. 2013. PMID: 23178755 Free PMC article.
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.
Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci G. Wang H, et al. AAPS J. 2013 Jan;15(1):242-9. doi: 10.1208/s12248-012-9427-5. Epub 2012 Nov 22. AAPS J. 2013. PMID: 23180159 Free PMC article.
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci G. Huang X, et al. Clin Cancer Res. 2013 May 1;19(9):2355-67. doi: 10.1158/1078-0432.CCR-12-3191. Epub 2013 Mar 14. Clin Cancer Res. 2013. PMID: 23493348 Free PMC article.
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Jones D, Heerema NA, Lozanski G, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, Blum W. Mims AS, et al. Haematologica. 2018 Jun;103(6):982-987. doi: 10.3324/haematol.2017.186890. Epub 2018 Mar 22. Haematologica. 2018. PMID: 29567781 Free PMC article. Clinical Trial.
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N. Mani R, et al. Haematologica. 2018 Aug;103(8):1288-1297. doi: 10.3324/haematol.2018.188193. Epub 2018 May 17. Haematologica. 2018. PMID: 29773600 Free PMC article.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. DiNardo CD, et al. Among authors: mims as. N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2. N Engl J Med. 2018. PMID: 29860938 Free article. Clinical Trial.
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.
Eisfeld AK, Kohlschmidt J, Mrózek K, Mims A, Walker CJ, Blachly JS, Nicolet D, Orwick S, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Wang ES, Stone RM, de la Chapelle A, Byrd JC, Bloomfield CD. Eisfeld AK, et al. Leukemia. 2018 Dec;32(12):2536-2545. doi: 10.1038/s41375-018-0147-4. Epub 2018 Jun 5. Leukemia. 2018. PMID: 29872168 Free PMC article.
Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD.
Wall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, Yang S, Wu H, Bostic M, Jaglowski S, Brammer JE, William B, Choe H, Mims AS, Penza S, Efebera Y, Devine S, Cataland S, Davies SM, Vasu S. Wall SA, et al. Among authors: mims as. Blood Adv. 2018 Oct 23;2(20):2619-2628. doi: 10.1182/bloodadvances.2018020321. Blood Adv. 2018. PMID: 30327370 Free PMC article.
112 results